Teva Pharmaceuticals, founded in 1901 , has been a key player in the Biopharma, Health Care, and Pharmaceutical industries for over a century. With a strong commitment to global leadership in generic and specialty medicines, the company boasts a robust portfolio of 3,500 products covering almost every therapeutic area. Recognized for its significant innovative research and operations, Teva serves approximately 200 million people worldwide every day, making it a vital contributor to the pharmaceutical industry. Noteworthy is the $100.00M Post-IPO Equity investment on 13 November 2023, which reinforces its appeal to investors. This investment, secured from Royalty Pharma, signifies a promising future for the company, as it continues to expand its presence in both generics and specialty and biopharmaceutical products. Teva Pharmaceuticals' headquarters in Israel serve as the hub for its numerous operations and one of the largest and most complex supply chains in the pharmaceutical industry. As the company continues to evolve and expand its product offerings, its influence and impact on global healthcare are set to grow. For more information, visit www.tevapharm.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $100.00M | 1 |
|
13 Nov 2023 |
| Post-IPO Debt | $2.25B | - | 27 Feb 2023 | |
| Post-IPO Equity | $358.00M | 1 |
|
14 Feb 2018 |
No recent news or press coverage available for Teva Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
